Studies have increasingly indicated that SCD is associated with specific and distinctive underlying AD pathological events, such as abnormal amyloid-β (Aβ) load [3] and tau deposition [4], reduced temporal cortical thickness [5] and hippocampal volume [6], disruptions in white matter [7], reduced glucose metabolism [8], and brain functional abnormalities [9]. This evidence concerns the gene MAPT and Alzheimer disease.